<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557306</url>
  </required_header>
  <id_info>
    <org_study_id>CBT101_P1</org_study_id>
    <nct_id>NCT04557306</nct_id>
  </id_info>
  <brief_title>Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer</brief_title>
  <official_title>An Open, 3+3 Design With Dose De-escalation, Single-center, Phase 1 Trial to Evaluate Tolerabiility and Safety of Intravenously Administered CBT101, an Autologous Natural Killer Cell, in Patients Who Underwent Curative Surgery and Adjuvant Therapy for Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHABiotech CO., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHABiotech CO., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate tolerability and safety of CBT101 in patients who&#xD;
      underwent curative surgery and adjuvant therapy for solid cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 12, 2020</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival rate (DFS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oerall survival rate (OS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>CBT101 q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT101 (2-6 x 10^9 cells), every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT101 q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT101 (2-6 x 10^9 cells), every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CBT101 (2-6 x 10^9 cells), every 2 weeks</intervention_name>
    <description>CBT101 (2-6 x 10^9 cells), every 4 weeks</description>
    <arm_group_label>CBT101 q2w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CBT101 (2-6 x 10^9 cells), every 4 weeks</intervention_name>
    <description>CBT101 (2-6 x 10^9 cells), every 4 weeks</description>
    <arm_group_label>CBT101 q4w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female adults aged 19 years and older&#xD;
&#xD;
          2. Patients with solid tumors as below (1) histologically or cytologically confirmed&#xD;
             solid tumors (2) 4 - 12 weeks of last adjuvant therapy after radical operations and&#xD;
             adjuvant therapy&#xD;
&#xD;
          3. Life expectancy 6 months&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group perfornace status (ECOG PS) 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of leptomeningeal carcinomatosis or spinal cord compression&#xD;
&#xD;
          2. History of peritoneal carninomatosis&#xD;
&#xD;
          3. Hemoglobine less than 9.0g/dL&#xD;
&#xD;
          4. Absolute Neutrophil Count (ANC) less than 1.5x10^3/mm^3&#xD;
&#xD;
          5. Platelet count less than 75x10^9/L&#xD;
&#xD;
          6. Total bilitbinn grater than 1.5 times te upper limit of normal&#xD;
&#xD;
          7. Alanine amino transferase (ALT) greater than 3 times the upper limit of normal&#xD;
&#xD;
          8. Alanine phospatase (ALP) greater than 2.5 times the upper limit of normal&#xD;
&#xD;
          9. Uncontrolled hypertension&#xD;
&#xD;
         10. Intensive insuline therapy&#xD;
&#xD;
         11. Active infectious disease&#xD;
&#xD;
         12. Patients with hypersensitivity history or allergy to investigational product&#xD;
&#xD;
         13. Pregmant of lactating woman&#xD;
&#xD;
         14. Patients who have participated in another clinical trials witin 30 days before the&#xD;
             start of this clinical trial&#xD;
&#xD;
         15. Patients judged to be inappropriate for this study by the investigator with other&#xD;
             reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chan Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA Bundang Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chan Kim</last_name>
    <phone>+82 31 780 5000</phone>
    <email>larrel80@gmail.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

